SCHEMBL6894569

SCHEMBL6894569

C[CH]OC(=O)Oc1ccc(OC)cc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CES2 O00748 1/20 0.47
CES1 P23141 1/20 0.47
CA1 P00915 5/20 0.45
CA2 P00918 5/20 0.45
SMN1; SMN2 Q16637 3/20 0.44
LMNA P02545 2/20 0.44
CYP1A2 P05177 1/20 0.44
CYP2C9 P11712 1/20 0.44
CYP2C19 P33261 1/20 0.44
F3 P13726 1/20 0.44
CA12 O43570 1/20 0.44
CA7 P43166 1/20 0.44
CA9 Q16790 1/20 0.44
CA14 Q9ULX7 1/20 0.44
PARP1 P09874 1/20 0.44
PARP10 Q53GL7 1/20 0.44
PARP2 Q9UGN5 1/20 0.44
PARP4 Q9UKK3 1/20 0.44
GAA P10253 2/20 0.43
ALDH1A1 P00352 2/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6890425 0.84 LMNA (0.55) LMNACYP1A2CYP2C9CYP2C19GAA
SCHEMBL1398350 0.83 CES2 (0.58) CES2CES1CA1CA2SMN1; SMN2
SCHEMBL6895059 0.82 CES2 (0.49) CES2CES1LMNAPARP1KMT2A
SCHEMBL444563 0.82 MAPT (0.44) SMN1; SMN2GAAALDH1A1ATMMAPT
SCHEMBL6891207 0.79 MAPT (0.51) CA1CA2SMN1; SMN2LMNACYP1A2
SCHEMBL6892716 0.79 RAB9A (0.47) SMN1; SMN2LMNACYP2C19ALDH1A1THRB
SCHEMBL697317 0.79 CA1 (0.56) CES2CES1CA1CA2SMN1; SMN2
SCHEMBL5864967 0.79 CES2 (0.54) CES2CES1CA1CA2SMN1; SMN2
SCHEMBL1421470 0.78 GAA (0.58) CES2CES1CA1CA2SMN1; SMN2
SCHEMBL8065698 0.77 ESR2 (0.58) CES2CES1CA1CA2SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6677331-B2 HAVING SUBSTITUTED IMIDAZO(5,1-B)THIAZOLE GROUP AT 2-POSITION; MICROBIOCIDES AGAINST BETA-LACTAMASE PRODUCING BACTERIA AND RESISTANT PSEUDOMONAS MEIJI SEIKA KAISHA, LTD. (JP) 2004-01-13 US disclosed
US-20030149016-A1 Novel carbapenem derivatives KANO YUKO (JP) 2003-08-07 US disclosed
EP-1101766-A1 NOVEL CARBAPENEM DERIVATIVES MEIJI SEIKA KAISHA LTD. (JP) 2001-05-23 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030149016-A1 Novel carbapenem derivatives DPEP1, TMPRSS15, STK35 CES2 938/4885CES1 75/4885CA1 3642/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.